Paolo A. Ascierto, MD, discusses how results from the COLUMBUS trial affect the treatment landscape for patients with BRAF-mutant melanoma.
Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses how results from the COLUMBUS trial affect the treatment landscape for patients withBRAF-mutant melanoma.
Ascierto recommends choosing the combination encorafenib (Braftovi) plus binimetinib (Mektovi). While the efficacy appeared similar to other treatments, encorafenib may be considered the “best” BRAF inhibitor.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More